RxDoctor Payments Data

Michael Glavin, MD

Ophthalmology · la Grange Park, ILNPI 1437102886

Payments from drug & device makers

$653in general payments, 2019–2025

Across 28 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$200
  • AbbVie$169
  • Tarsus Pharmaceuticals, Inc.$60
  • Aerie Pharmaceuticals, Inc.$54
  • Bausch & Lomb Americas Inc.$50
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$46
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$57388%
  • Education$8012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$653 in reported general payments places this provider in the 35th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$305,415
Medicare patients
1,043
Services billed
3,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost51$31,101
RhopressaNetarsudil Mesylate30$14,678
Latanoprost1,338$14,395
Difluprednate80$8,478
Restasis MultidoseCyclosporine11$7,139
Bromfenac Sodium33$7,088
ProlensaBromfenac Sodium16$5,781
LumiganBimatoprost20$5,771
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat307$5,520
ZioptanTafluprost/Pf12$3,060
Prednisolone Acetate74$2,850
Brimonidine Tartrate206$2,779
Travoprost13$2,615
Timolol Maleate97$2,553
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$54$45,77881 claims
AbbVieRestasis Multidose, Lumigan$169$12,91031 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$46$5,78116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in la Grange Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →